TABLE 5.
RFS | OS | |||||
Variable | HR | 95% CI | P | HR | 95% CI | P |
EGC | ||||||
Age | 1.02 | 1.00 to 1.03 | 0.072 | 1.08 | 1.07 to 1.09 | <0.001 |
Female | 0.65 | 0.42 to 1.00 | 0.050 | 0.53 | 0.40 to 0.72 | <0.001 |
Submucosal invasion | 1.04 | 0.68 to 1.57 | 0.870 | 1.15 | 0.89 to 1.48 | 0.286 |
LN metastasis | 6.00 | 3.95 to 9.02 | <0.001 | 2.23 | 1.62 to 3.07 | <0.001 |
Histology and grade | ||||||
PD (vs WMD) | 0.77 | 0.50 to 1.20 | 0.255 | 0.96 | 0.71 to 1.29 | 0.772 |
SRC (vs WMD) | 0.37 | 0.19 to 0.71 | 0.003 | 0.66 | 0.44 to 0.98 | 0.041 |
AGC | ||||||
Age | 1.00 | 1.00 to 1.01 | 0.138 | 1.02 | 1.02 to 1.03 | <0.001 |
Female | 1.09 | 0.96 to 1.24 | 0.168 | 1.04 | 0.93 to 1.17 | 0.490 |
AJCC stage | ||||||
Stage II (vs stage I) | 3.67 | 2.47 to 5.46 | <0.001 | 2.12 | 1.60 to 2.81 | <0.001 |
Stage III (vs stage I) | 13.87 | 9.52 to 20.21 | <0.001 | 6.89 | 5.32 to 8.93 | <0.001 |
Histology and grade | ||||||
PD (vs WMD) | 1.14 | 0.99 to 1.31 | 0.063 | 1.23 | 1.09 to 1.40 | 0.001 |
SRC (vs WMD) | 1.22 | 1.02 to 1.46 | 0.033 | 1.45 | 1.22 to 1.71 | <0.001 |
AGC indicates advanced gastric cancer; CI, confidence interval, EGC, early gastric cancer; HR, hazard ratio; LN, lymph node; PD, poorly differentiated; RFS, Relapse-free survival; SRC, signet ring cell carcinoma; WMD, well-to-moderately differentiated.